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Abstract
Background: Because inheritance is recognized as playing a role in age at menarche and natural menopause, the
development of chemotherapy-induced amenorrhea (CIA) might depend on inherited genetic factors; however,
studies that explore such a correlation are few and have received scant attention. Given the importance of this
topic we conducted a comprehensive genotype study in young women (≤45 years) with early-stage breast cancer.
Methods: Our approach tested the effect of variant polymorphisms in drug metabolism enzymes (DMEs) using a
predesigned pharmacogenomics panel (TaqMan® OpenArray®, Life Technologies GmbH, Darmstadt, Germany) in
premenopausal women (n = 50). Patients received contemporary chemotherapy; in all cases a
cyclophosphamide-based regimen with a dose of at least 500 mg/m2 for six cycles. CIA was considered to be
present in women with no resumption of menstrual bleeding within 12 months after completion of chemotherapy
or goserelin.
Results: Twenty-six patients (52 %) showed CIA during follow-up whereas 24 women (48 %) remained
premenopausal. Of all the DMEs studied, only the SLCO1B1*5 (rs4149056) genotype was associated with the
development of CIA (P = 0.017). Of the 26 patients who were homozygous for the T/T allele SLCO1B1*5, 18 (69.2 %)
developed CIA compared with 8 (30.8 %) of the 22 patients who were heterozygous (C/T allele). The association of
heterozygous SLCO1B1*5 allele (OR 0.038; 95%CI: 0.05–0.92) with a lower risk of developing CIA remained
significant in a binary logistic regression analysis that include age, SLCO1B1*5 allele variants, and goserelin therapy.
Conclusions: Patient age and SLCO1B1*5 allele variants predict the likelihood of young women with breast cancer
developing CIA.
Keywords: Breast cancer, Chemotherapy-induced amenorrhea, OpenArray genotyping, Single nucleotide
polymorphism, SLCO1B1
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Background
In Germany, 10 % of all newly diagnosed breast cancers
are detected in the age group under 45 years old [1]. Pa-
tients younger than 50 years of age, especially those with
hormone-insensitive breast cancer, achieve significant
benefit from adjuvant systemic chemotherapy in terms
of prolonged disease-free and overall survival [2]. How-
ever, a considerable number of these young patients will
suffer from chemotherapy-induced amenorrhea (CIA)
thereafter, depending on age at diagnosis and type of
chemotherapy used [3].
Premenopausal women in whom amenorrhea developed
as a consequence of adjuvant breast cancer therapy had
significantly better disease-free and overall survival than
did women without amenorrhea, particularly when the
tumor was estrogen receptor (ER)-positive [4]. Interest-
ingly, the dose of the chemotherapy drug delivered was
not a key factor in accounting for these differences [5].
Apart from its impact on survival and the loss of fertility,
CIA due to premature ovarian failure leads to subjective
and objective menopausal symptoms, which can nega-
tively affect short- and long-term quality of life [6, 7].
Apart from its relationship with patient age at the time
of therapy, there are no proven patient characteristics
that are predictive of CIA [3, 8]. Pretreatment anti-
Müllerian hormone (AMH), a biomarker of ovarian re-
serve, appears to be a potential predictor of CIA in
women with early breast cancer [9]. However, further
studies are needed in order to define the regimen-
specific action of chemotherapy on AMH levels, the per-
centage of post-treatment recovery of AMH levels, and
the relationship between menopausal status and AMH
[10]. Because inheritance is recognized as playing a role
in age at menarche and natural menopause [11, 12], the
development of CIA might also depend on inherited
genetic factors; however, studies that explore such a cor-
relation are few and have received scant attention [13].
Previous pharmacogenetic investigations on CIA have
focused on alkylating-based regimens. Cyclophospha-
mide is a pro-drug that requires activation by multiple
cytochrome P450 (CYP450) enzymes [14]. The effect of
cyclophosphamide on ovarian toxicity in patients with
systemic lupus erythematosus has been found to be as-
sociated with the CYP2C19 genotype [15–17]. In an-
other study women with CYP3A*1B variant genotype
demonstrated a higher risk of ovarian failure after
cyclophosphamide-based chemotherapy [18]. In conflict
with these data, a pilot study investigating six CYP450
genotypes (n = 20) did not reveal a genetic effect on CIA
in women with breast cancer receiving anthracycline-
and cyclophosphamide-based therapy [19].
Solute carrier (SLC) transporters mediate the influx of
cytotoxic drugs into cells. Organic anion-transporting
polypeptides (OATPs) encoded by the solute carrier
organic anion (SLCO) genes constitute an important
transporter superfamily that mediates transmembrane
transport of various clinical drugs and endogenous nu-
trients. Eleven human OATPs with different transport
functions are expressed in various tissues. Many import-
ant clinical drugs have been identified as substrates of
liver-specific OATP1B1 and OATP1B3 [20, 21].
SLCO1B1 encodes the organic anion-transporting poly-
peptide OATP1B1, which mediates the hepatic uptake of
various drugs [22]. Previous studies have shown associa-
tions between genetic polymorphisms in SLCO genes and
the uptake pharmacokinetics of their substrates. A common
single-nucleotide variation (coding DNA c.521 T >C, pro-
tein p.V174A, rs4149056) in the SLCO1B1 gene decreases
the transporting activity of OATP1B1, resulting in markedly
increased plasma concentrations of many statins, for ex-
ample [23].
Given the importance of this topic we planned a more
comprehensive genotype study in a larger cohort of
young women with early breast cancer. Our approach
tested the effect of variant polymorphisms in drug me-
tabolism enzymes (DMEs) using a predesigned pharma-




A total of 50 premenopausal patients diagnosed with early-
stage breast cancer between July 2001 and January 2011
were included in this prospective cohort analysis. All pa-
tients were aged ≤45 years at the time of diagnosis and
were suitable to receive pre- or postoperative chemother-
apy. In all cases patients received a cyclophosphamide-
based regimen with a defined dose of at least 500 mg/m2 of
body surface area for six cycles. Details of the protocols
used in terms of administration of anthracyclines and/or
taxanes are listed in Table 1.
Only 30 % (n = 15) of all cases had hormone-
insensitive breast cancer. Women with hormone
receptor-positive disease (n = 35) received tamoxifen in a
dosage of 20 mg daily for 5 years. Additionally, 50 % (n
= 25) of included patients were treated with the
gonadotrophin-releasing hormone (GnRH) agonist
goserelin, 3.6 mg subcutaneously every 4 weeks, in two
different clinical situations: 1) concurrent treatment with
chemotherapy in hormone-insensitive breast cancer ac-
cording to the ZOladex Rescue of Ovarian function
(ZORO) study protocol (n = 4) [24]; or 2) concurrent
and/or sequential goserelin application for a maximum
of 2 years in hormone receptor-positive disease (n = 21).
Clinical outcomes
At enrollment before chemotherapy, all women were pre-
menopausal as defined by regularly occuring menstrual
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cycles. Follow-up assessment of menopausal status was
performed 12 months after chemotherapy completion or
12 months from discontinuation of goserelin treatment.
Normal ovarian function was defined as two consecutive
menstrual periods within 21 to 35 days in a timeframe of
5 to 8 months after last administration of chemotherapy
or goserelin. CIA was considered to be present in women
with no resumption of menstrual bleeding within
12 months after completion of chemotherapy or goserelin.
Plasma levels of follicle-stimulating hormone (FSH) and
estradiol (E2) were measured during follow-up for sero-
logic definition of menopausal status.
DNA extraction and DME genotyping
Venous blood samples were taken prior to chemotherapy
using PAXgene Blood DNA tubes (Qiagen, Hilden,
Germany). DNA was purified according to the manufac-
turer’s instructions for the PAXgene Blood DNA kit (Qia-
gen) in a single-tube procedure. The homogenization of
lysates was optimized by biopolymer-shredding system
(QIAshredder, Qiagen). Extracted DNA was assessed with
a micro-volume spectrophotometer (NanoDrop 8000,
Fisher Scientific GmbH, Schwerte, Germany) and by ana-
lysis of housekeeping gene expression using conventional
polymerase chain reaction (PCR). Additional DNA quanti-
fication was performed using Quant-iT™ DNA Assay kit
(Invitrogen, Carlsbad, CA, USA), resulting in an optimal
DNA concentration of 50 ng/μL.
The TaqMan® OpenArray® Pharmacogenomics (PGx)
Panel (Life Technologies GmbH, Darmstadt, Germany)
was used for genotyping analysis of DMEs and associ-
ated transport proteins. This OpenArray® genotyping
plate includes assays for preformatted targets on a 192-
well format (16 samples per panel; 3 sub-arrays per sam-
ple). Each TaqMan® DME Genotyping Assay contains
two allele-specific probes and a primer pair to detect the
specific SNP target. A total of 29 genes are covered
across 164 unique assays (gene list available in
Additional file 1: Table S1). Data were analyzed with
OpenArray® SNP Genotyping Analysis software and then
imported into TaqMan® Genotyper™ software.
Statistical analysis
The Chi-squared test and Fisher’s exact test were used
to compare categorical variables. The Mann-Whitney U-
test was performed to compare continuous variables,
and Spearman’s correlation coefficient is given, where
appropriate. Binary logistic regression was performed to
analyze the impact of factors predictive of CIA. Disease-
free survival was analyzed using Kaplan-Meier method,
with the log-rank test for comparison of subgroups. All
analyses were conducted with the IBM SPSS Statistics
Package, version 20 (IBM Deutschland GmbH, Ehnin-
gen, Germany). In all tests P < 0.05 was considered sta-
tistically significant, and all P-values cited were from
two-tailed tests.
We performed post hoc analysis to estimate the statis-
tical power of the described logistic regression analysis
using the G*Power 3.1.9.2 tool [25]. Two-tailed analysis
for prediction of CIA by the rs4149056 polymorphism
with an α error of 0.05 revealed a statistical power of
70 % for our sample size.
Results
Fifty subjects with complete data sets were included in
this analysis. Twenty-six patients (52 %) showed CIA
during follow-up whereas 24 women (48 %) remained
premenopausal throughout the study. Among CIA sub-
group (n = 26), serologic FSH and E2 assessment after
completion of chemotherapy or goserelin confirmed
peri- or postmenopausal status in the majority of cases:
15 postmenopausal (57.7 %), 8 perimenopausal (30.8 %),
and 3 premenopausal (11.5 %). Table 2 shows the demo-
graphic and tumor characteristics for both subgroups
(remained premenopausal vs. CIA). The only significant
differences between the two groups were age (P = 0.001)
and total duration of menstruation (P = 0.005). As ex-
pected, women who experienced CIA were significantly
older than those who did not.
On analyzing the 164 assays of the PGx panel with re-
spect to CIA, no statistics were computed for 89 assays
(54.3 %) because results of these targets were constant,
and 23 further assays (14 %) were excluded from the
Table 1 Summary of regimens used for pre- or postoperative chemotherapy in premenopausal women with early-stage breast







TAC 23 (46 %) 6 3 500 mg/m2 50 mg/m2 (A) 75 mg/m2
FEC 15 (30 %) 6 3 500 mg/m2 90 mg/m2 (E) –
TC 8 (16 %) 6 3 600 mg/m2 – 75 mg/m2
EC 2 (4 %) 6 3 600 mg/m2 90 mg/m2 (E) –
FAC 1 (2 %) 6 3 500 mg/m2 50 mg/m2 (A) –
AC 1 (2 %) 6 3 600 mg/m2 60 mg/m2 (A) –
T Taxotere® (docetaxel), A adriamycin (doxorubicin), C cyclophosphamide, F fluorouracil, E epirubicin
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analysis because their frequencies were not in Hardy-
Weinberg equilibrium. The remained 52 assays of inter-
est were assessed for data quality, resulting in 34 finally
evaluated assays (20.7 %) with complete and reprodu-
cible data sets (Additional file 2: Table S2, Additional file
3: Table S3).
Of all the DMEs studied, only the genotype of
SLCO1B1*5 (rs4149056) was associated with the devel-
opment of CIA (P = 0.017). Of the 26 patients who were
homozygous for the SLCO1B1*5 T/T allele, 18 (69.2 %)
developed CIA, compared with 8 (33.3 %) of the 24 pa-
tients who were either heterozygous or homozygous for
the C allele (Table 3). SLCO1B1*5 genotype allele distri-
bution as a function of chemotherapeutic regimen and
patient age group is presented in Tables 4 and 5. The
correlation between rs4149056 polymorphism and CIA
was significant (Spearman rs = 0.378, P = 0.007).
Furthermore, the association of heterozygous
SLCO1B1*5 allele with a lower risk of developing CIA
remained significant on binary logistic regression ana-
lysis that include factors with a P-value < 0.2 in the uni-
variate setting: age groups, SLCO1B1*5 allele variants,
and goserelin therapy (Table 6). The protective effect of
heterozygous SLCO1B1*5 allele regarding occurrence of
CIA (odds ratio 0.22; 95 % CI 0.05–0.92) appears to be
unrelated to patient age at initiation of chemotherapy.
Regression analysis revealed that age (odds ratio for
≥40 years: 5.44; 95 % CI 1.29–22.9) contributed signifi-
cantly to the model, indicating that age and SLCO1B1*5
allele variants predict the likelihood of developing CIA.
Among this premenopausal study cohort, a recurrence
of breast cancer was detected in 10 cases (20 %) during
a median follow-up of 61 months (range 18–120
months). Disease-free survival was not related to occur-
rence of CIA (log-rank test, P = 0.526), SLCO1B1*5
genotype (P = 0.793), or age group (P = 0.985) using
Kaplan-Meier method.
Discussion
CIA is relevant because 25 % of women diagnosed with
breast cancer are premenopausal, and previous studies
suggest that CIA may impact breast cancer survival and
patient’s quality of life due to premature ovarian failure
with associated infertility and menopausal symptoms in
women younger than 50 years.
Currently, little is known about the genetics of
chemotherapy-induced ovarian failure and CIA. It is
possible that the same genetic changes that are associ-
ated with premature menopause might also predict
treatment-induced menopause [13]. A second category
of candidate genes might be those that are implicated in
drug metabolism. These include transporters involved in
absorption and distribution, and in renal or hepatic
elimination, and enzymes of drug metabolism that are
Table 2 Demographic and tumor characteristics of study






Mean age in years (± SD) 36.7 (4.8) 41.1 (4.0) 0.001




Mean age in years
at menarche (± SD)




23.4 (5.1) 28.1 (4.8) 0.005













Estrogen receptor status: 0.55
Positive 15 19
Negative 9 7




















* denotes missing values
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usually present in the liver or gastrointestinal tract. SNPs
in drug transporters, metabolizing enzymes and drug
targets have the potential to affect therapeutic efficacy
and toxicity [26, 27].
Our study results are a further example of the import-
ance of variant polymorphisms predicting toxicities from
chemotherapy in breast cancer patients. Using a phar-
macogenomic approach permitting rapid scan of mul-
tiple markers, a significant association with CIA in
Causasian women was found only for the SLCO1B1*5
allele distribution (rs4149056) (Table 6). In particular,
patients who have the homozygous (T/T) genotype of
the rs4149056 polymorphism showed a higher risk for
developing CIA compared with patients who have the
homozygous (C/C) or heterozygous (C/T) genotype.
In a genome-wide study the SEARCH Collaborative
Group has identified the rs4149056 C allele in SLCO1B1
as being strongly associated with an increased risk of
statin-induced myopathy [28]. No SNPs in any other re-
gion were clearly associated with myopathy. Several clin-
ical studies in the past have investigated associations
between rs4149056 SLCO1B1 genotypes and statin
pharmacokinetics [22]. Although not all yielded signifi-
cant results, the collective evidence indicates that statin
blood concentrations are higher in people with the C al-
lele [28].
Substrates for OATP1B1 include anticancer agents like
methotrexate [29], gimatecan, SN-38 (the active metab-
olite of irinotecan), and pazopanib [23]. Certain
SLCO1B1 variants associated with enhanced clearance
of methotrexate increase the risk of gastrointestinal tox-
icity when this compound is used to treat children with
acute lymphoblastic leukemia [30].
Endogenous substrates of SLCO1B1 include steroid
hormone conjugates such as estradiol-17β-glucuronide
and estrone-3-sulfate [31]. In a nested case-control study
in the California Teachers Study cohort, only genetic
variation in SLCO1B1 was associated with breast cancer
risk. There was also an indication that estrogen-
progestin therapy (EPT) may interact with SNPs in
SLCO1B1; one variant (rs4149013) was significantly as-
sociated with breast cancer risk in EPT users [32].
Furthermore, given the frequent occurrence of over-
lapping substrate specificities – and the fact that func-
tionally important coding-region SNPs in genes
encoding members of some transporters families may
not be common – it might be most fruitful to focus on
combinations of coding-region SNPs in genes encoding
transporters that work in parallel or in series [33]. In our
data (Additional file 4: Table S4), alongside the described
significant SLCO1B1*5 polymorphism in relation to
CIA, there was a trend for a second SLC transporter
genotype (SLC15A2: rs2257212, rs2293616) to be associ-
ated with menopausal status after completion of chemo-
therapy (P = 0.093).
In addition to the novel described potential genetic
risk factor (SNP rs4149056) for CIA, increased age is un-
equivocally associated with higher rates of CIA. Older
women, often defined as those at least 40 years old, are
more sensitive to chemotherapy-related ovarian ablation
[3]. This can be attributed to the decreasing number of
active ovarian follicles with increasing age [34]. Taking
the cut-off of 40 years, we found significantly different
incidences of CIA in the age group <40 years (30.4 %)
compared with the subgroup ≥40 years (70.4 %) when
using contemporary chemotherapeutic regimens. Re-
cently, the pharmacogenetic pilot study by Wessels et al.
[19] including common variant alleles for CYP450 en-
zymes found no differences in genotype frequencies but,
Table 3 SLCO1B1*5 genotype allele distribution as a function of








T/T (n = 26) 8 (33.3 %) 18
(69.2 %)
0.017
C/T (n = 22) 14 (58.3 %) 8 (30.8 %)
C/C (n = 2) 2 (8.4 %) 0
Table 4 SLCO1B1*5 genotype allele distribution as a function of














T/T 12 9 4 0 0 1 0.714
C/T 10 6 3 2 1 0
C/C 1 0 1 0 0 0
T Taxotere® (docetaxel), A adriamycin (doxorubicin), C cyclophosphamide, F
fluorouracil, E epirubicin
Table 5 SLCO1B1*5 genotype allele distribution as a function of










T/T 5 6 11 4 0.703
C/T 5 7 8 2
C/C 0 0 1 1
Table 6 Binary logistic regression for prediction of CIA:
SLCO1B1*5 allele distribution and goserelin therapy as
co-variates adjusted for age
Co-variates P-value Odds ratio 95 % CI
age (<40 vs. ≥40 years) 0.021 5.44 1.29–22.9
rs4149056 (T/T) 0.115 – –
rs4149056 (C/C) 0.999 – –
rs4149056 (C/T) 0.038 0.22 0.05–0.92
Goserelin therapy (no vs. yes) 0.17 0.49 0.18–1.35
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as expected, women who experienced CIA were signifi-
cantly older than those who did not (P = 0.009). The risk
of CIA in young patients with breast cancer (≤47 years)
does not appear to be related to BRCA1 or BRCA2 mu-
tation status [35]. Again, age at treatment and use of
tamoxifen were important predictors of CIA in women
who carry a BRCA1 or BRCA2 mutation.
The major limitations of the study are the limited case
number (n = 50) leading to a reduced statistical power of
70 %, and the inclusion of patients with goserelin treat-
ment. Previous studies have suggested that temporary
ovarian suppression with a GnRH analogue may pre-
serve ovarian function both in humans and animal
models [36]. However, the clinical data are conflicting.
For example, the ZORO study randomised 60 ER-
negative patients with breast cancer to anthracycline-
and taxane-based chemotherapy alone or in combination
with goserelin and found that there was no statistical
difference in the resumption of ovarian function between
the two groups [24]. This finding is confirmed in recent
publications of other prospective trials [37, 38]. Cur-
rently, following publication of the Prevention of Early
Menopause Study (POEMS) results [39, 40], the use of
GnRH agonists during adjuvant chemotherapy outside
clinical trials is being re-evaluated. Our data showed a
trend for preservation of menstrual bleeding in patients
receiving goserelin treatment concurrently with chemo-
therapy, but the difference was not statistically signifi-
cant (Table 2). Administration of goserelin sequentially
to chemotherapy as endocrine therapy in ER-positive
disease had no impact on the occurrence of CIA.
Other methodologic concerns include inconsistencies
in defining CIA and variability in the use of chemothera-
peutic agents and tamoxifen in heterogeneous study
population, depending on hormone-receptor status.
However, our data do not support the hypothesis or pre-
vious findings that taxane-based chemotherapy or tam-
oxifen may have an impact on CIA (Table 2). For
example, Najafi et al. [41] have reported that the type of
chemotherapy is an important risk factor for CIA and
that taxane-based regimens induced more CIA than
other regimens. Non-cyclophosphamide treated controls
or breast cancer patients without chemotherapy were
not included in our study.
The lack of a consistent definition across breast cancer
literature complicates incidence comparisons between dif-
ferent regimens and studies. The definition of CIA ranges
from one missed period within 1 year to continuous cessa-
tion of menses for more than 1 year [3]. In summary, irre-
versible amenorrhea lasting for several (>12) months
following chemotherapy and an FSH level of ≥30 IU/L in
the presence of a negative pregnancy test seems to be an
appropriate characterization of chemotherapy-induced
ovarian failure [42]. We used strict criteria to define CIA
as no resumption of menstrual bleeding within 12 months
after completion of chemotherapy or goserelin. However,
cessation of menses is not synonymous with true ovarian
failure because estrogen levels can remain in the premen-
opausal range even where CIA persists for 1 year or longer
(as in 10 % of our cases with CIA).
Conclusions
This pharmacogenomics study revealed a genetic effect on
CIA in Caucasian women with early breast cancer receiving
standard contemporary chemotherapy. The impact on CIA
is due to genotype distribution of the SLC drug transporter
gene SLCO1B1*5. A prospective validation of this finding is
required in a larger cohort of premenopausal women using
clearly predefined inclusion criteria (e.g., no treatment with
goserelin). These data illustrate the potential power for pre-
dicting CIA based on a more profound understanding of
inherited genetic factors.
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